 In the United States, an application to market modafinil for pediatric ADHD was submitted to the FDA, but approval was denied due to major concerns over the occurrence of Stevens–Johnson syndrome in clinical trials.Modafinil and armodafinil have been studied as a complement to antipsychotic medications in the treatment of schizophrenia.They have been consistently shown to have no effect on positive symptoms or cognitive performance.